Zenas BioPharma Statistics

Total Valuation

Zenas BioPharma has a market cap or net worth of $480.26 million. The enterprise value is $169.10 million.

Market Cap	480.26M
Enterprise Value	169.10M

Important Dates

The last earnings date was Thursday, May 15, 2025, before market open.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Zenas BioPharma has 41.83 million shares outstanding. The number of shares has increased by 1,408.82% in one year.

Current Share Class	41.83M
Shares Outstanding	41.83M
Shares Change (YoY)	+1,408.82%
Shares Change (QoQ)	-0.31%
Owned by Insiders (%)	0.88%
Owned by Institutions (%)	49.49%
Float	17.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	17.80
Forward PS	n/a
PB Ratio	1.69
P/TBV Ratio	1.69
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	11.27
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.47, with a Debt / Equity ratio of 0.00.

Current Ratio	6.47
Quick Ratio	6.39
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -115.47% and return on invested capital (ROIC) is -71.22%.

Return on Equity (ROE)	-115.47%
Return on Assets (ROA)	-56.70%
Return on Invested Capital (ROIC)	-71.22%
Return on Capital Employed (ROCE)	-61.00%
Revenue Per Employee	$115,385
Profits Per Employee	-$1.25M
Employee Count	130
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

In the past 12 months, Zenas BioPharma has paid $224,000 in taxes.

Income Tax	224,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	9.01
200-Day Moving Average	n/a
Relative Strength Index (RSI)	61.99
Average Volume (20 Days)	135,648

Short Selling Information

The latest short interest is 4.87 million, so 11.64% of the outstanding shares have been sold short.

Short Interest	4.87M
Short Previous Month	4.39M
Short % of Shares Out	11.64%
Short % of Float	28.32%
Short Ratio (days to cover)	22.79

Income Statement

In the last 12 months, Zenas BioPharma had revenue of $15.00 million and -$162.76 million in losses. Loss per share was -$7.00.

Revenue	15.00M
Gross Profit	-136.41M
Operating Income	-173.64M
Pretax Income	-54.46M
Net Income	-162.76M
EBITDA	-173.51M
EBIT	-173.64M
Loss Per Share	-$7.00

Full Income Statement

Balance Sheet

The company has $312.38 million in cash and $1.23 million in debt, giving a net cash position of $311.15 million or $7.44 per share.

Cash & Cash Equivalents	312.38M
Total Debt	1.23M
Net Cash	311.15M
Net Cash Per Share	$7.44
Equity (Book Value)	284.32M
Book Value Per Share	6.80
Working Capital	268.68M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$137.62 million and capital expenditures -$127,000, giving a free cash flow of -$137.75 million.

Operating Cash Flow	-137.62M
Capital Expenditures	-127,000
Free Cash Flow	-137.75M
FCF Per Share	-$3.29

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,157.60%
Pretax Margin	-1,083.58%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Zenas BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,408.82%
Shareholder Yield	-1,408.82%
Earnings Yield	-33.89%
FCF Yield	-28.68%

Dividend Details

Analyst Forecast

The average price target for Zenas BioPharma is $32.29, which is 181.27% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$32.29
Price Target Difference	181.27%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zenas BioPharma has an Altman Z-Score of 3.66 and a Piotroski F-Score of 2.

Altman Z-Score	3.66
Piotroski F-Score	2